STARR CHRISTOPHER M
SEC Form 4 insider trading activity
STARR CHRISTOPHER M has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 5, 2026.
On the most recent filing, STARR CHRISTOPHER M is listed as Director at Monopar Therapeutics. Inside the rolling window, STARR CHRISTOPHER M reported no open-market purchases and 1 open-market sale totaling $659K in MNPR.
Companies traded
Other insiders at MNPR
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$659K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has STARR CHRISTOPHER M made?
STARR CHRISTOPHER M has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does STARR CHRISTOPHER M trade?
STARR CHRISTOPHER M has filed SEC Form 4 disclosures for 1 company, including MNPR.
When was STARR CHRISTOPHER M's most recent SEC Form 4 filing?
STARR CHRISTOPHER M's most recent SEC Form 4 filing on Tracefour is dated Oct 5, 2026.
What is STARR CHRISTOPHER M's total buy and sell value in the current window?
Inside the rolling retention window, STARR CHRISTOPHER M bought $0 and sold $659K based on SEC Form 4 filings.
What was STARR CHRISTOPHER M's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,400 MNPR shares on 2026-10-01, worth $659K, per SEC Form 4 filings.